| Dr Gerald Lynn Franke, DDS | |
|
24861 Del Prado, Dana Point, CA 92629-2853 | |
| (949) 661-6255 | |
| (949) 661-7736 |
| Full Name | Dr Gerald Lynn Franke |
|---|---|
| Gender | Male |
| Speciality | Dentist - General Practice |
| Location | 24861 Del Prado, Dana Point, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255563037 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1223G0001X | Dentist - General Practice | 32071 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Gerald Lynn Franke, DDS 24861 Del Prado, Dana Point, CA 92629-2853 Ph: (949) 661-6255 | Dr Gerald Lynn Franke, DDS 24861 Del Prado, Dana Point, CA 92629-2853 Ph: (949) 661-6255 |
News Archive
An academic team which includes key researchers from the Universities of Manchester and Hull has taken both first and second prizes, in a nationwide innovation competition run by Microsoft.
In a preliminary clinical trial, investigators at Johns Hopkins have shown that even partially matched bone marrow transplants can eliminate sickle cell disease in some patients, ridding them of painful and debilitating symptoms and the need for a lifetime of pain medications and blood transfusions.
VIVUS, Inc. today announced positive results from a phase 2 study evaluating the safety and efficacy of Qnexa®, an investigational drug, for the treatment of obstructive sleep apnea (OSA). VIVUS recently completed phase 3 development of Qnexa for the treatment of obesity and submitted a New Drug Application (NDA) to the FDA for that indication.
GlycoVaxyn, a pioneer in the development of innovative bioconjugate vaccines, has commenced a Phase I clinical study with its vaccine candidate (GVXN SD133) against Shigella dysenteriae, a cause of serious intestinal infections. This is the first product from the company to enter clinical evaluation.
Karolinska Development: Pharmanest AB announced today positive results from a Phase II-study investigating the efficacy and tolerability of SHACT. The data show that SHACT is effective in reducing pain in connection with intrauterine device insertion. Karolinska Development owns 63% of Pharmanest.
› Verified 1 days ago
Jeffrey R. Kindseth, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 24721 La Plz, Dana Point, CA 92629 Phone: 949-661-2152 | |
Nazanin Alameh Zadeh, DDS Dentist Medicare: Medicare Enrolled Practice Location: 24060 Camino Del Avion Ste 4b, Dana Point, CA 92629 Phone: 858-349-9770 | |
Dr. Herbert Sheldon Malmon, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 32515 Golden Lantern St, Suite D, Dana Point, CA 92629 Phone: 949-661-2000 Fax: 949-661-4438 | |
Dr. Meghan Dianne Mcdonough, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 32932 Pacific Coast Hwy Ste 19, Dana Point, CA 92629 Phone: 949-487-7779 | |
Dr. Garrett Bryon Rubio, D.D.S. Dentist Medicare: Not Enrolled in Medicare Practice Location: 24861 Del Prado, Dana Point, CA 92629 Phone: 949-661-6255 Fax: 949-661-7736 | |
Dr. Mark A Cruz, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 32241 Crown Valley Parkway, #200, Dana Point, CA 92629 Phone: 949-661-1006 Fax: 949-661-9454 | |
Eileen Abdollahi, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 22882 Via Genoa, Dana Point, CA 92629 Phone: 949-836-8271 |